Conversion from valproic acid onto topiramate in adolescents and adults with epilepsy

Acta Neurologica Scandinavica

Volumn 119, Issue 5, 2009, Pages 304-312

  Schreiner, A ^a   Stollhoff, K ^b   Ossig, W ^c   Unkelbach, S ^d   Luer W ^e   Bogdanow, M ^f   Schauble, Barbara ^a  

^a JANSSEN CILAG GMBH   (Germany)

^b Private Practice   (Germany)

^c Private Practice   (Germany)

^d ClinAssess ^*  (Germany)

^e Private Practice   (Germany)

^f CLINASSESS GMBH   (Germany)

Author keywords

Epilepsy; QOLIE 10; Topiramate; Valproic acid

Indexed keywords

TOPIRAMATE; VALPROIC ACID;

ADOLESCENT; ADULT; AGED; ALOPECIA; ARTICLE; ATAXIA; BLOOD CLOTTING DISORDER; BRAIN DAMAGE; BRAIN DISEASE; CHILD; CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; EDEMA; EPILEPSY; ERYTHEMA MULTIFORME; EVENING DOSAGE; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HYPERACTIVITY; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; PARESTHESIA; QUALITY OF LIFE; SCHOOL CHILD; SEIZURE; SIDE EFFECT; SPEECH DISORDER; TINNITUS; TREMOR; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; EPILEPSY; FEMALE; FRUCTOSE; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME; VALPROIC ACID; YOUNG ADULT;

EID: 64549163726     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2008.01130.x     Document Type: Article

References (40)

1. Aldenkamp A, Vigevano F, Arzimanoglou A, Covanis A. Role of valproate across the ages. Treatment of epilepsy in children. Acta Neurol Scand Suppl 2006 184 : 1 13.
2. Perucca E, Aldenkamp A, Tallis R, Kramer G. Role of valproate across the ages. Treatment of epilepsy in the elderly. Acta Neurol Scand Suppl 2006 184 : 28 37.
3. Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N Engl J Med 1992 327 : 765 71.
4. Marson AG, Al-Kharusi AM, Alwaidh M et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007 369 : 1016 26.
5. Mikkonen K, Vainionpaa LK, Pakarinen AJ et al. Long-term reproductive endocrine health in young women with epilepsy during puberty. Neurology 2004 62 : 445 50.
6. Morrell MJ, Isojarvi J, Taylor AE et al. Higher androgens and weight gain with valproate compared with lamotrigine for epilepsy. Epilepsy Res 2003 54 : 189 99.
7. Pylvanen V, Knip M, Pakarinen A, Kotila M, Turkka J, Isojarvi JI. Serum insulin and leptin levels in valproate-associated obesity. Epilepsia 2002 43 : 514 7.
8. Walia KS, Khan EA, Ko DH, Raza SS, Khan YN. Side effects of antiepileptics - a review. Pain Pract 2004 4 : 194 203.
9. Joffe H, Cohen LS, Suppes T et al. Longitudinal follow-up of reproductive and metabolic features of valproate-associated polycystic ovarian syndrome features: a preliminary report. Biol Psychiatry 2006 60 : 1378 81.
10. Prabhakar S, Sahota P, Kharbanda PS et al. Sodium valproate, hyperandrogenism and altered ovarian function in Indian women with epilepsy: a prospective study. Epilepsia 2007 48 : 1371 7.
11. Leppik IE, Birnbaum A. Epilepsy in the elderly. Semin Neurol 2002 22 : 309 20.
12. Perucca E, Aldenkamp A, Tallis R, Kramer G. Role of valproate across the ages. Treatment of epilepsy in the elderly. Acta Neurol Scand Suppl 2006 184 : 28 37.
13. Scheyer RD. Valproic acid - drug interactions. In Levy RH, Mattson R, Meldrum BS, Perucca E, eds. Antiepileptic drugs. Philadelphia : Lippincott, 2002 801 7.
14. Fakhoury TA, Hammer AE, Vuong A, Messenheimer JA. Efficacy and tolerability of conversion to monotherapy with lamotrigine compared with valproate and carbamazepine in patients with epilepsy. Epilepsy Behav 2004 5 : 532 8.
15. Ben-Menachem E. Preliminary efficacy of levetiracetam in monotherapy. Epileptic Disord 2003 5 (Suppl. 1 S51 5.
16. Arroyo S, Dodson WE, Privitera MD et al. Randomized dose-controlled study of topiramate as first-line therapy in epilepsy. Acta Neurol Scand 2005 112 : 214 22.
17. Gilliam FG, Veloso F, Bomhof MA et al. A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy. Neurology 2003 60 : 196 202.
18. Biton V, Montouris GD, Ritter F et al. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group. Neurology 1999 52 : 1330 7.
19. Bialer M, Doose DR, Murthy B et al. Pharmacokinetic interactions of topiramate. Clin Pharmacokinet 2004 43 : 763 80.
20. Cramer JA, Arrigo C, Van HG, Bromfield EB. Comparison between the QOLIE-31 and derived QOLIE-10 in a clinical trial of levetiracetam. Epilepsy Res 2000 41 : 29 38.
21. Cramer JA, Perrine K, Devinsky O, Meador K. A brief questionnaire to screen for quality of life in epilepsy: the QOLIE-10. Epilepsia 1996 37 : 577 82.
22. Privitera MD, Brodie MJ, Mattson RH, Chadwick DW, Neto W, Wang S. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003 107 : 165 75.
23. Bourgeois BF. Reducing overtreatment. Epilepsy Res 2002 52 : 53 60.
24. Clopper C, Pearson S. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934 26 : 404 13.
25. Bent S, Padula A, Avins AL. Brief communication: Better ways to question patients about adverse medical events: a randomized, controlled trial. Ann Intern Med 2006 144 : 257 61.
26. Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia 2001 42 : 1255 60.
27. Berg AT. Defining intractable epilepsy. Adv Neurol 2006 97 : 5 10.
28. Guerrini R, Carpay J, Groselj J et al. Topiramate monotherapy as broad-spectrum antiepileptic drug in a naturalistic clinical setting. Seizure 2005 14 : 371 80.
29. Peeters K, Adriaenssen I, Wapenaar R, Neto W, Pledger G. A pooled analysis of adjunctive topiramate in refractory partial epilepsy. Acta Neurol Scand 2003 108 : 9 15.
30. Luciano AL, Shorvon SD. Results of treatment changes in patients with apparently drug-resistant chronic epilepsy. Ann Neurol 2007 62 : 375 81.
31. Brodie MJ, Yuen AW. Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group. Epilepsy Res 1997 26 : 423 32.
32. Beydoun A, Kutluay E. Conversion to monotherapy: clinical trials in patients with refractory partial seizures. Neurology 2003 60 : S13 25.
33. Sachdeo RC, Reife RA, Lim P, Pledger G. Topiramate monotherapy for partial onset seizures. Epilepsia 1997 38 : 294 300.
34. Schmidt D. Strategies to prevent overtreatment with antiepileptic drugs in patients with epilepsy. Epilepsy Res 2002 52 : 61 9.
35. Ben-Menachem E, Henriksen O, Dam M et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 1996 37 : 539 43.
36. McElroy SL, Frye MA, Altshuler LL et al. A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders. Bipolar Disord 2007 9 : 426 34.
37. Stenlof K, Rossner S, Vercruysse F, Kumar A, Fitchet M, Sjostrom L. Topiramate in the treatment of obese subjects with drug-naive type 2 diabetes. Diabetes Obes Metab 2007 9 : 360 8.
38. Ben-Menachem E, Axelsen M, Johanson EH, Stagge A, Smith U. Predictors of weight loss in adults with topiramate-treated epilepsy. Obes Res 2003 11 : 556 62.
39. El Yaman SH, Mroueh SM, Sinno DD, Mikati MA. Long-term patterns of weight changes during topiramate therapy: an observational study. Neurology 2007 69 : 310 1.
40. Liang Y, She P, Wang X, Demarest K. The messenger RNA profiles in liver, hypothalamus, white adipose tissue, and skeletal muscle of female Zucker diabetic fatty rats after topiramate treatment. Metabolism 2006 55 : 1411 9.